Jeztiq

Dienogest/Ethinylestradiol, the active ingredient in Jeztiq, is a combined oral contraceptive presented as an oral tablet for oral use. It combines a progestogenic component with an estrogenic component to provide reliable contraception and to treat certain menstrual disorders in women of reproductive age.

GNH USA supplies Jeztiq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing quality‑assured products that meet European Union regulatory standards and supporting global healthcare delivery through robust supply chain management and compliance monitoring.

Jeztiq, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent ovulation and manage menstrual conditions.

- Prevention of pregnancy: provides reliable contraceptive protection by inhibiting ovulation. - Dysmenorrhea: reduces menstrual pain and improves cycle regularity. - Menstrual cycle disorders: helps regulate irregular periods and decrease heavy bleeding.

Jeztiq may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often occurring early in treatment. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: mild to moderate headaches during the cycle. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Arterial thrombosis: risk of heart attack or stroke. - Severe hypertension: sudden high blood pressure.

Before prescribing Jeztiq, clinicians should consider several safety factors.

- Assess thrombotic risk: evaluate personal or family history of clotting disorders before initiating therapy. - Screen for hypertension: measure blood pressure and monitor regularly during use. - Avoid smoking: especially in women over 35 years of age due to increased cardiovascular risk. - Review liver function: contraindicated in severe hepatic disease or impairment. - Perform pregnancy test: ensure the patient is not pregnant prior to starting the contraceptive. - Store at ambient temperature: keep tablets in the original packaging, protect from moisture and heat.

Jeztiq can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Rifampin therapy: can decrease hormone levels and increase risk of unintended pregnancy.

Moderate Interactions (Monitor Closely): - Antibiotics such as ampicillin or tetracycline: may slightly lower contraceptive effectiveness. - St. John’s Wort herbal supplement: may reduce hormone concentrations. - Antifungal azoles (e.g., ketoconazole): can increase hormone levels and risk of side effects. - Certain antiretroviral protease inhibitors: may alter metabolism of the contraceptive components.